Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00389896 | A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED) | PHASE3 | COMPLETED | 150 | — | — | Jul 26, 2001 | Oct 4, 2002 | Aug 15, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0733 / Duration of Treatment: 18 Weeks | DRUG | - |
| Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks | DRUG | - |
Inclusion Criteria: * Patient has stable Type 2 diabetes mellitus at Visit 1. * Patient meets screening criteria based on Visit 1 lab tests Exclusion Criteria: * Patient is pregnant, breastfeeding, or at risk of becoming pregnant * Patient has heart disease, uncontrolled high blood pressure, or o...